Paris-based venture capital firm Sofinnova Partners has closed the oversubscribed Sofinnova Crossover Fund at €445m (US$540m). The fund is the largest of its kind in Europe and the only one with a team solely dedicated to growth-stage opportunities in healthcare. Sofinnova said that it will maintain its focus on European clinical-stage companies needing scale-up capital…
©2022 All rights reserved LaingBuisson 
.){kind=link}